ASH 2016 | Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients

Harry Erba

Press brief by Harry Erba, MD, PhD, of The University of Alabama At Birmingham, Birmingham, AL, on a Phase 1b Study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Share this video  
Similar topics